Please provide your email address to receive an email when new articles are posted on . The highest percentages of patients with HBsAg loss were observed in the groups that received xalnesiran plus an ...

Please provide your email address to receive an email when new articles are posted on . Adjusted analysis demonstrated no association between nucleos(t)ide analogue retreatment and HBsAg seroclearance ...

Patients with chronic hepatitis B virus (HBV) infection in the immune-tolerant phase may still experience hepatic inflammation and disease progression, and could benefit from early antiviral treatment ...

If a doctor suspects that a person may have hepatitis B, they will likely order a single blood test to check for the condition. This test is called a hepatitis B titer panel, and it consists of three ...

A combination treatment involving tobevibart and elebsiran significantly improved disease activity in adults with chronic ...

Mean HBsAg reduction of 1.23 log 10 IU/mL at week 12 with a favorable safety and tolerability profile WARMINSTER, Pa., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), ...

Professor of Medicine and Chief, Division of Hepatology, Center for Liver Disease, University of Miami School of Medicine, Miami, Florida Antiviral studies generally used intermediate markers of ...

At the end of treatment, 33.3% of patients receiving imdusiran for 48 weeks, interferon (IFN) for 24 weeks and ongoing nucleoside analogue (NA) therapy achieved undetectable levels of HBsAg that were ...

Phase Ib study combining ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with CD20-positive B-cell non-Hodgkin lymphoma (NHL). This is an ASCO ...

BEIJING - About 93 million Chinese, or 7.18 percent of the total population are hepatitis B surface antigen (HBsAg) carriers, the Ministry of Health (MOH) said on Monday. The country sees a ...